SCHEMBL23923341

SCHEMBL23923341

Cc1ccc(N(C)C(=O)[C@H](Cc2ccccc2)NC(=O)CNC(=O)c2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
SLC6A9 P48067 1/20 0.47
GPR139 Q6DWJ6 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.46
RAB9A P51151 2/20 0.45
KDM1A O60341 1/20 0.45
MAOA P21397 1/20 0.45
ATM Q13315 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
LMNA P02545 1/20 0.44
POLB P06746 1/20 0.44
CTSL P07711 2/20 0.44
CTSS P25774 1/20 0.44
CTSK P43235 1/20 0.44
CTSB P07858 1/20 0.43
CCR2 P41597 2/20 0.43
NPC1 O15118 1/20 0.43
ACE P12821 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23923343 1.00 KMT2A (0.47) KMT2ASLC6A9GPR139SMN1; SMN2RAB9A
SCHEMBL23923396 0.93 GPR139 (0.51) KMT2ASLC6A9GPR139RAB9AKDM1A
SCHEMBL23923394 0.93 GPR139 (0.51) KMT2ASLC6A9GPR139RAB9AKDM1A
SCHEMBL23923355 0.90 SLC6A9 (0.54) KMT2ASLC6A9GPR139RAB9AATM
SCHEMBL23923324 0.90 SLC6A9 (0.51) SLC6A9GPR139RAB9AKDM1AMAOA
SCHEMBL23923326 0.90 SLC6A9 (0.51) SLC6A9GPR139RAB9AKDM1AMAOA
SCHEMBL23923352 0.90 SLC6A9 (0.54) KMT2ASLC6A9GPR139RAB9AATM
SCHEMBL23923365 0.85 GPR139 (0.54) KMT2ASLC6A9GPR139RAB9AATM
SCHEMBL23923528 0.85 GPR139 (0.54) KMT2ASLC6A9GPR139SMN1; SMN2RAB9A
SCHEMBL23923530 0.85 GPR139 (0.54) KMT2ASLC6A9GPR139SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11850247-B2 Antiviral compounds REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2023-12-26 US disclosed
US-20210322416-A1 ANTIVIRAL COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-10-21 US disclosed
US-20210322416-A1 ANTIVIRAL COMPOUNDS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11850247-B2 Antiviral compounds ZC3HAV1, ZC3HAV1L, CD4 KMT2A 3667/4885SLC6A9 2550/4885GPR139 2504/4885
US-20210322416-A1 ANTIVIRAL COMPOUNDS ZC3HAV1, ZC3HAV1L, CD4 KMT2A 3667/4885SLC6A9 2550/4885GPR139 2504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.